Global Flu Vaccine Market Research Report 2026

Flu Vaccine Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Flu Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Flu Vaccine refers to a preventive biological product that uses seasonal or potentially pandemic strains as antigens to reduce influenza-related morbidity and complications through human immunization strategies. Its technological pathways encompass inactivated and live-attenuated platforms and can switch among different manufacturing systems (egg-based, cell-culture, recombinant protein, etc.) to address antigenic drift and annual strain updates. On the regulatory side, a seasonal “recommendation–update–release” cadence has been institutionalized (as reflected in WHO position papers and national immunization guidelines), alongside a consistent framework for dosage forms, routes of administration, and eligible populations (e.g., programmatic annual vaccination for individuals ≥6 months of age). Within this framework, the vaccine functions both as a public-health intervention and as a vehicle for global supply-chain coordination and regulatory-science iteration, embodying end-to-end alignment “from strain selection, process engineering, and quality control to vaccination scenarios.”

Market Opportunities & Drivers: How can the convergence of “annual immunization + technology evolution + policy support” reshape value?The steady reinforcement of annual immunization strategies creates a predictable clinical setting for vaccination (e.g., ACIP’s routine annual recommendation for individuals ≥6 months), while the EU’s seasonal strain recommendations and pandemic fast-track pathways together establish a clear “policy–manufacture–release” supply continuum. On the technology side, cell-based and recombinant protein platforms improve adaptability to rapidly evolving strains; differentiated options such as high-dose/adjuvanted inactivated vaccines and intranasal live-attenuated formulations further segment value across populations. In the United States, authorization for intranasal vaccines to be administered at home by patients/caregivers broadens reach and adherence. Leading manufacturers are simultaneously investing in capacity and modernized processes (e.g., new high-dose Flu Vaccine units in France) to add resilience against demand swings across pandemic and seasonal scenarios. Challenges persist around strain-match uncertainty, coordination across dual seasons in different hemispheres, and ongoing commitments to cold-chain and compliance. Industry/Supply Chain: How does the closed loop from “antigen—manufacturing line—vaccination setting” to “brand—channel—service” take shape? Upstream relies on seed stocks, controlled substrates (eggs/cell lines), and excipient systems under modular quality and clinical standards. Midstream facilities with multi-platform capabilities support rapid seasonal strain switches and intra-year dual-season rotations across intercontinental networks in Europe, North America, and Australia. Representative companies include Sanofi (recombinant/high-dose portfolio), CSL Seqirus (cell-based and adjuvanted combinations with sites across the US/EU/Australia), GSK (Fluarix/FluLaval), AstraZeneca (FluMist/Fluenz intranasal LAIV), as well as active producers in China and Japan such as Hualan Bio, Changchun Institute of Biological Products (WHO-PQ), Sinovac, BCHT (intranasal LAIV), Jiangsu GDK, and KM Biologics (Japan, HA-split). Downstream, national immunization programs, pharmacies, and primary-care networks work in concert; in some markets, “home delivery and self-administration” is emerging, enriching access modes and real-world vaccination scenarios. Segmentation Trends: Which populations and settings are shaping differentiated product positions? Older adults and people with comorbidities increasingly prefer “immune-enhanced” approaches, making high-dose/adjuvanted inactivated vaccines a focal point in clinical dialogue. Pediatric and school settings value needle-free convenience and mucosal immunity; intranasal live-attenuated Flu Vaccines have accumulated long-term real-world evidence in certain markets and have expanded to home self-/caregiver administration. Markets sensitive to egg-based constraints—or seeking faster strain switches—show rising interest in cell-based and recombinant technologies. Public-health and emergency-preparedness bodies emphasize integrated readiness for both seasonal and potential pandemic use, advancing standby supply and rapid-switch mechanisms with manufacturers. Overall, a “population–platform–setting” triad is taking shape: multiple technologies coexist within the same market to meet diverse clinical needs. Regional Trends: How do North America, Europe, and Asia-Pacific each play to their strengths in strategy and supply? North America is characterized by strong alignment of guidelines and channels: CDC’s annual consensus is well established, and pharmacy networks plus home-administration options widen reach. Europe leverages EMA’s programmatic processes for seasonal composition and pandemic vaccines, emphasizing scientific consistency and rapid response. China and the broader Asia-Pacific accelerate “localized production + convergence with international norms”: some enterprises have obtained WHO-PQ and serve multiple markets, while Japanese manufacturers maintain in-country production with institutionalized annual strain updates, forming a stable regional supply. In sum, North America and Europe reinforce mature “standards–channels–compliance” linkages, while Asia-Pacific advances on “localized capacity—platform diversity—outbound supply.”Latest DevelopmentsApril 1, 2025: EMA issued Flu Vaccine composition recommendations for the 2025/2026 season, reaffirming the WHO-guided annual strain-update mechanism and providing a consistent basis for EU registrations and lot release；

September 20, 2024: AstraZeneca announced that FluMist in the United States was approved for self-/caregiver administration at home, expanding access and convenience for intranasal live-attenuated vaccination；May 13, 2024: Sanofi announced capacity expansion in France for high-dose Flu Vaccines and related capabilities, strengthening Europe’s seasonal and emergency manufacturing resilience.

This report delivers a comprehensive overview of the global Flu Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Flu Vaccine. The Flu Vaccine market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Flu Vaccine market comprehensively. Regional market sizes by Type, by Application, by Route of Administration, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Flu Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Flu Vaccine Market Report

Chapter Outline

1.1 Product Definition

1.2 Flu Vaccine by Type

1.2.1 Global Flu Vaccine Market Value by Type: 2025 vs 2032

1.2.2 Trivalent Influenza Vaccine

1.2.3 Quadrivalent Influenza Vaccine

1.3 Flu Vaccine by Route of Administration

1.3.1 Global Flu Vaccine Market Value by Route of Administration: 2025 vs 2032

1.3.2 Intramuscular

1.3.3 Intranasal

1.4 Flu Vaccine by Application

1.4.1 Global Flu Vaccine Market Value by Application: 2025 vs 2032

1.4.2 6 Months to 3 Years

1.4.3 > 3 Years

1.5 Global Flu Vaccine Market Size Estimates and Forecasts

1.5.1 Global Flu Vaccine Revenue 2021–2032

1.5.2 Global Flu Vaccine Sales 2021–2032

1.5.3 Global Flu Vaccine Market Average Price (2021–2032)

1.6 Assumptions and Limitations

2.1 Global Flu Vaccine Sales Market Share by Manufacturers (2021–2026)

2.2 Global Flu Vaccine Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Flu Vaccine Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Flu Vaccine, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Flu Vaccine, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Flu Vaccine, Product Types and Applications

2.7 Global Key Manufacturers of Flu Vaccine, Date of Entry into the Industry

2.8 Global Flu Vaccine Market Competitive Situation and Trends

2.8.1 Global Flu Vaccine Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Flu Vaccine Players Market Share by Revenue

2.8.3 Global Flu Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Flu Vaccine Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Flu Vaccine Sales by Region: 2021–2032

3.2.1 Global Flu Vaccine Sales by Region: 2021–2026

3.2.2 Global Flu Vaccine Sales by Region: 2027–2032

3.3 Global Flu Vaccine Revenue by Region: 2021–2032

3.3.1 Global Flu Vaccine Revenue by Region: 2021–2026

3.3.2 Global Flu Vaccine Revenue by Region: 2027–2032

3.4 North America Flu Vaccine Market Facts & Figures by Country

3.4.1 North America Flu Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Flu Vaccine Sales by Country (2021–2032)

3.4.3 North America Flu Vaccine Revenue by Country (2021–2032)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Flu Vaccine Market Facts & Figures by Country

3.5.1 Europe Flu Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Flu Vaccine Sales by Country (2021–2032)

3.5.3 Europe Flu Vaccine Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Flu Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Flu Vaccine Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Flu Vaccine Sales by Region (2021–2032)

3.6.3 Asia Pacific Flu Vaccine Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Flu Vaccine Market Facts & Figures by Country

3.7.1 Latin America Flu Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Flu Vaccine Sales by Country (2021–2032)

3.7.3 Latin America Flu Vaccine Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Flu Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Flu Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Flu Vaccine Sales by Country (2021–2032)

3.8.3 Middle East and Africa Flu Vaccine Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Flu Vaccine Sales by Type (2021–2032)

4.1.1 Global Flu Vaccine Sales by Type (2021–2026)

4.1.2 Global Flu Vaccine Sales by Type (2027–2032)

4.1.3 Global Flu Vaccine Sales Market Share by Type (2021–2032)

4.2 Global Flu Vaccine Revenue by Type (2021–2032)

4.2.1 Global Flu Vaccine Revenue by Type (2021–2026)

4.2.2 Global Flu Vaccine Revenue by Type (2027–2032)

4.2.3 Global Flu Vaccine Revenue Market Share by Type (2021–2032)

4.3 Global Flu Vaccine Price by Type (2021–2032)

5.1 Global Flu Vaccine Sales by Application (2021–2032)

5.1.1 Global Flu Vaccine Sales by Application (2021–2026)

5.1.2 Global Flu Vaccine Sales by Application (2027–2032)

5.1.3 Global Flu Vaccine Sales Market Share by Application (2021–2032)

5.2 Global Flu Vaccine Revenue by Application (2021–2032)

5.2.1 Global Flu Vaccine Revenue by Application (2021–2026)

5.2.2 Global Flu Vaccine Revenue by Application (2027–2032)

5.2.3 Global Flu Vaccine Revenue Market Share by Application (2021–2032)

5.3 Global Flu Vaccine Price by Application (2021–2032)

6.1 Sanofi

6.1.1 Sanofi Company Information

6.1.2 Sanofi Description and Business Overview

6.1.3 Sanofi Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Sanofi Flu Vaccine Product Portfolio

6.1.5 Sanofi Recent Developments/Updates

6.2 CSL

6.2.1 CSL Company Information

6.2.2 CSL Description and Business Overview

6.2.3 CSL Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 CSL Flu Vaccine Product Portfolio

6.2.5 CSL Recent Developments/Updates

6.3 GSK

6.3.1 GSK Company Information

6.3.2 GSK Description and Business Overview

6.3.3 GSK Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 GSK Flu Vaccine Product Portfolio

6.3.5 GSK Recent Developments/Updates

6.4 AstraZeneca

6.4.1 AstraZeneca Company Information

6.4.2 AstraZeneca Description and Business Overview

6.4.3 AstraZeneca Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 AstraZeneca Flu Vaccine Product Portfolio

6.4.5 AstraZeneca Recent Developments/Updates

6.5 Hualan Bio

6.5.1 Hualan Bio Company Information

6.5.2 Hualan Bio Description and Business Overview

6.5.3 Hualan Bio Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Hualan Bio Flu Vaccine Product Portfolio

6.5.5 Hualan Bio Recent Developments/Updates

6.6 Changchun Institute of Biological

6.6.1 Changchun Institute of Biological Company Information

6.6.2 Changchun Institute of Biological Description and Business Overview

6.6.3 Changchun Institute of Biological Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Changchun Institute of Biological Flu Vaccine Product Portfolio

6.6.5 Changchun Institute of Biological Recent Developments/Updates

6.7 Sinovac

6.7.1 Sinovac Company Information

6.7.2 Sinovac Description and Business Overview

6.7.3 Sinovac Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Sinovac Flu Vaccine Product Portfolio

6.7.5 Sinovac Recent Developments/Updates

6.8 BCHT

6.8.1 BCHT Company Information

6.8.2 BCHT Description and Business Overview

6.8.3 BCHT Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 BCHT Flu Vaccine Product Portfolio

6.8.5 BCHT Recent Developments/Updates

6.9 Jiangsu GDK

6.9.1 Jiangsu GDK Company Information

6.9.2 Jiangsu GDK Description and Business Overview

6.9.3 Jiangsu GDK Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Jiangsu GDK Flu Vaccine Product Portfolio

6.9.5 Jiangsu GDK Recent Developments/Updates

6.10 KM Biologics

6.10.1 KM Biologics Company Information

6.10.2 KM Biologics Description and Business Overview

6.10.3 KM Biologics Flu Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.10.4 KM Biologics Flu Vaccine Product Portfolio

6.10.5 KM Biologics Recent Developments/Updates

7.1 Flu Vaccine Industry Chain Analysis

7.2 Flu Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Flu Vaccine Production Mode & Process Analysis

7.4 Flu Vaccine Sales and Marketing

7.4.1 Flu Vaccine Sales Channels

7.4.2 Flu Vaccine Distributors

7.5 Flu Vaccine Customer Analysis

8.1 Flu Vaccine Industry Trends

8.2 Flu Vaccine Market Drivers

8.3 Flu Vaccine Market Challenges

8.4 Flu Vaccine Market Restraints

8.5 Impact of U.S. Tariffs

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

 Table 1. Global Flu Vaccine Market Value by Type (US$ Million), 2025 vs 2032

 Table 2. Global Flu Vaccine Market Value by Route of Administration (US$ Million), 2025 vs 2032

 Table 3. Global Flu Vaccine Market Value by Application (US$ Million), 2025 vs 2032

 Table 4. Global Flu Vaccine Market Competitive Situation by Manufacturers in 2025

 Table 5. Global Flu Vaccine Sales (M Doses) of Key Manufacturers (2021–2026)

 Table 6. Global Flu Vaccine Sales Market Share by Manufacturers (2021–2026)

 Table 7. Global Flu Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)

 Table 8. Global Flu Vaccine Revenue Share by Manufacturers (2021–2026)

 Table 9. Global Market Flu Vaccine Average Price (USD/Doses) of Key Manufacturers (2021–2026)

 Table 10. Global Key Players of Flu Vaccine, Industry Ranking, 2023 vs 2024 vs 2025

 Table 11. Global Key Manufacturers of Flu Vaccine, Manufacturing Sites and Headquarters

 Table 12. Global Key Manufacturers of Flu Vaccine, Product Types and Applications

 Table 13. Global Key Manufacturers of Flu Vaccine, Date of Entry into the Industry

 Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

 Table 15. Global Flu Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on Flu Vaccine Revenue, 2025

 Table 16. Manufacturers Mergers & Acquisitions, Expansion Plans

 Table 17. Global Flu Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 18. Global Flu Vaccine Sales by Region (M Doses), 2021–2026

 Table 19. Global Flu Vaccine Sales Market Share by Region (2021–2026)

 Table 20. Global Flu Vaccine Sales by Region (M Doses), 2027–2032

 Table 21. Global Flu Vaccine Sales Market Share by Region (2027–2032)

 Table 22. Global Flu Vaccine Revenue by Region (US$ Million), 2021–2026

 Table 23. Global Flu Vaccine Revenue Market Share by Region (2021–2026)

 Table 24. Global Flu Vaccine Revenue by Region (US$ Million), 2027–2032

 Table 25. Global Flu Vaccine Revenue Market Share by Region (2027–2032)

 Table 26. North America Flu Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 27. North America Flu Vaccine Sales by Country (M Doses), 2021–2026

 Table 28. North America Flu Vaccine Sales by Country (M Doses), 2027–2032

 Table 29. North America Flu Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 30. North America Flu Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 31. Europe Flu Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 32. Europe Flu Vaccine Sales by Country (M Doses), 2021–2026

 Table 33. Europe Flu Vaccine Sales by Country (M Doses), 2027–2032

 Table 34. Europe Flu Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 35. Europe Flu Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 36. Asia Pacific Flu Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

 Table 37. Asia Pacific Flu Vaccine Sales by Region (M Doses), 2021–2026

 Table 38. Asia Pacific Flu Vaccine Sales by Region (M Doses), 2027–2032

 Table 39. Asia Pacific Flu Vaccine Revenue by Region (US$ Million), 2021–2026

 Table 40. Asia Pacific Flu Vaccine Revenue by Region (US$ Million), 2027–2032

 Table 41. Latin America Flu Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 42. Latin America Flu Vaccine Sales by Country (M Doses), 2021–2026

 Table 43. Latin America Flu Vaccine Sales by Country (M Doses), 2027–2032

 Table 44. Latin America Flu Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 45. Latin America Flu Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 46. Middle East and Africa Flu Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 47. Middle East and Africa Flu Vaccine Sales by Country (M Doses), 2021–2026

 Table 48. Middle East and Africa Flu Vaccine Sales by Country (M Doses), 2027–2032

 Table 49. Middle East and Africa Flu Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 50. Middle East and Africa Flu Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 51. Global Flu Vaccine Sales (M Doses) by Type (2021–2026)

 Table 52. Global Flu Vaccine Sales (M Doses) by Type (2027–2032)

 Table 53. Global Flu Vaccine Sales Market Share by Type (2021–2026)

 Table 54. Global Flu Vaccine Sales Market Share by Type (2027–2032)

 Table 55. Global Flu Vaccine Revenue (US$ Million) by Type (2021–2026)

 Table 56. Global Flu Vaccine Revenue (US$ Million) by Type (2027–2032)

 Table 57. Global Flu Vaccine Revenue Market Share by Type (2021–2026)

 Table 58. Global Flu Vaccine Revenue Market Share by Type (2027–2032)

 Table 59. Global Flu Vaccine Price (USD/Doses) by Type (2021–2026)

 Table 60. Global Flu Vaccine Price (USD/Doses) by Type (2027–2032)

 Table 61. Global Flu Vaccine Sales (M Doses) by Application (2021–2026)

 Table 62. Global Flu Vaccine Sales (M Doses) by Application (2027–2032)

 Table 63. Global Flu Vaccine Sales Market Share by Application (2021–2026)

 Table 64. Global Flu Vaccine Sales Market Share by Application (2027–2032)

 Table 65. Global Flu Vaccine Revenue (US$ Million) by Application (2021–2026)

 Table 66. Global Flu Vaccine Revenue (US$ Million) by Application (2027–2032)

 Table 67. Global Flu Vaccine Revenue Market Share by Application (2021–2026)

 Table 68. Global Flu Vaccine Revenue Market Share by Application (2027–2032)

 Table 69. Global Flu Vaccine Price (USD/Doses) by Application (2021–2026)

 Table 70. Global Flu Vaccine Price (USD/Doses) by Application (2027–2032)

 Table 71. Sanofi Company Information

 Table 72. Sanofi Description and Business Overview

 Table 73. Sanofi Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 74. Sanofi Flu Vaccine Product

 Table 75. Sanofi Recent Developments/Updates

 Table 76. CSL Company Information

 Table 77. CSL Description and Business Overview

 Table 78. CSL Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 79. CSL Flu Vaccine Product

 Table 80. CSL Recent Developments/Updates

 Table 81. GSK Company Information

 Table 82. GSK Description and Business Overview

 Table 83. GSK Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 84. GSK Flu Vaccine Product

 Table 85. GSK Recent Developments/Updates

 Table 86. AstraZeneca Company Information

 Table 87. AstraZeneca Description and Business Overview

 Table 88. AstraZeneca Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 89. AstraZeneca Flu Vaccine Product

 Table 90. AstraZeneca Recent Developments/Updates

 Table 91. Hualan Bio Company Information

 Table 92. Hualan Bio Description and Business Overview

 Table 93. Hualan Bio Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 94. Hualan Bio Flu Vaccine Product

 Table 95. Hualan Bio Recent Developments/Updates

 Table 96. Changchun Institute of Biological Company Information

 Table 97. Changchun Institute of Biological Description and Business Overview

 Table 98. Changchun Institute of Biological Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 99. Changchun Institute of Biological Flu Vaccine Product

 Table 100. Changchun Institute of Biological Recent Developments/Updates

 Table 101. Sinovac Company Information

 Table 102. Sinovac Description and Business Overview

 Table 103. Sinovac Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 104. Sinovac Flu Vaccine Product

 Table 105. Sinovac Recent Developments/Updates

 Table 106. BCHT Company Information

 Table 107. BCHT Description and Business Overview

 Table 108. BCHT Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 109. BCHT Flu Vaccine Product

 Table 110. BCHT Recent Developments/Updates

 Table 111. Jiangsu GDK Company Information

 Table 112. Jiangsu GDK Description and Business Overview

 Table 113. Jiangsu GDK Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 114. Jiangsu GDK Flu Vaccine Product

 Table 115. Jiangsu GDK Recent Developments/Updates

 Table 116. KM Biologics Company Information

 Table 117. KM Biologics Description and Business Overview

 Table 118. KM Biologics Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses), and Gross Margin (2021–2026)

 Table 119. KM Biologics Flu Vaccine Product

 Table 120. KM Biologics Recent Developments/Updates

 Table 121. Key Raw Materials Lists

 Table 122. Raw Materials Key Suppliers Lists

 Table 123. Flu Vaccine Distributors List

 Table 124. Flu Vaccine Customers List

 Table 125. Flu Vaccine Market Trends

 Table 126. Flu Vaccine Market Drivers

 Table 127. Flu Vaccine Market Challenges

 Table 128. Flu Vaccine Market Restraints

 Table 129. Research Programs/Design for This Report

 Table 130. Key Data Information from Secondary Sources

 Table 131. Key Data Information from Primary Sources

 Table 132. Authors List of This Report

List of Figures

 Figure 1. Product Picture of Flu Vaccine

 Figure 2. Global Flu Vaccine Market Value by Type (US$ Million), 2021–2032

 Figure 3. Global Flu Vaccine Market Share by Type: 2025 & 2032

 Figure 4. Trivalent Influenza Vaccine Product Picture

 Figure 5. Quadrivalent Influenza Vaccine Product Picture

 Figure 6. Global Flu Vaccine Market Value by Route of Administration (US$ Million), 2021–2032

 Figure 7. Global Flu Vaccine Market Share by Route of Administration: 2025 vs 2032

 Figure 8. Intramuscular Product Picture

 Figure 9. Intranasal Product Picture

 Figure 10. Global Flu Vaccine Market Value by Application (US$ Million), 2021–2032

 Figure 11. Global Flu Vaccine Market Share by Application: 2025 & 2032

 Figure 12. 6 Months to 3 Years

 Figure 13. > 3 Years

 Figure 14. Global Flu Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032

 Figure 15. Global Flu Vaccine Market Size (US$ Million), 2021–2032

 Figure 16. Global Flu Vaccine Sales (M Doses), 2021–2032

 Figure 17. Global Flu Vaccine Average Price (USD/Doses), 2021–2032

 Figure 18. Flu Vaccine Report Years Considered

 Figure 19. Flu Vaccine Sales Share by Manufacturers in 2025

 Figure 20. Global Flu Vaccine Revenue Share by Manufacturers in 2025

 Figure 21. Top 5 and Top 10 Global Flu Vaccine Players: Market Share by Revenue in Flu Vaccine in 2025

 Figure 22. Flu Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

 Figure 23. Global Flu Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Figure 24. North America Flu Vaccine Sales Market Share by Country (2021–2032)

 Figure 25. North America Flu Vaccine Revenue Market Share by Country (2021–2032)

 Figure 26. U.S. Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 27. Canada Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 28. Europe Flu Vaccine Sales Market Share by Country (2021–2032)

 Figure 29. Europe Flu Vaccine Revenue Market Share by Country (2021–2032)

 Figure 30. Germany Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 31. France Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 32. U.K. Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 33. Italy Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 34. Russia Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 35. Asia Pacific Flu Vaccine Sales Market Share by Region (2021–2032)

 Figure 36. Asia Pacific Flu Vaccine Revenue Market Share by Region (2021–2032)

 Figure 37. China Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 38. Japan Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 39. South Korea Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 40. India Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 41. Australia Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 42. China Taiwan Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 43. Indonesia Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 44. Thailand Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 45. Malaysia Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 46. Latin America Flu Vaccine Sales Market Share by Country (2021–2032)

 Figure 47. Latin America Flu Vaccine Revenue Market Share by Country (2021–2032)

 Figure 48. Mexico Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 49. Brazil Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 50. Argentina Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 51. Middle East and Africa Flu Vaccine Sales Market Share by Country (2021–2032)

 Figure 52. Middle East and Africa Flu Vaccine Revenue Market Share by Country (2021–2032)

 Figure 53. Turkey Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 54. Saudi Arabia Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 55. UAE Flu Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 56. Global Sales Market Share of Flu Vaccine by Type (2021–2032)

 Figure 57. Global Revenue Market Share of Flu Vaccine by Type (2021–2032)

 Figure 58. Global Flu Vaccine Price (USD/Doses) by Type (2021–2032)

 Figure 59. Global Sales Market Share of Flu Vaccine by Application (2021–2032)

 Figure 60. Global Revenue Market Share of Flu Vaccine by Application (2021–2032)

 Figure 61. Global Flu Vaccine Price (USD/Doses) by Application (2021–2032)

 Figure 62. Flu Vaccine Value Chain

 Figure 63. Channels of Distribution (Direct Vs Distribution)

 Figure 64. Bottom-up and Top-down Approaches for This Report

 Figure 65. Data Triangulation

 Figure 66. Key Executives Interviewed